These findings highlight the specific role of IRG1/itaconate in promoting tumor immunogenicity and suggest that targeting the tumor-intrinsic IRG1-itaconate axis could be a viable strategy for improving cancer immunotherapy. The gene discussed is ACOD1; the disease is cancer.